Choice of the 3rd and the 4th line therapy sequence in patients with metastatic colorectal cancer
Journal: Злокачественные опухоли @malignanttumors
Section: Оригинальные исследования
Article in issue: 1 т.16, 2026.
Free access
Introduction: Treatment options in the third line for patients with metastatic colorectal cancer are limited in the Russian Federation to the multikinase inhibitor regorafenib and the strategy of re-administering previously effective chemo-targeted therapy (hereinafter referred to as chemotherapy re-challenge).Aim: To evaluate the efficacy and safety of regorafenib and chemotherapy re-challenge in later lines of therapy for metastatic colorectal cancer, and to identify patient subgroups deriving the greatest clinical benefit from the upfront choice of each approach.
Short address: https://sciup.org/140315012
IDS: 140315012 | DOI: 10.18027/2224-5057-2026-072